Radioiodine treatment of hyperthyroidism: Fixed or calculated doses; intelligent design or science? [3]

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 11, 2007, Pages 1883-1884

  Van Isselt, Johannes W ^a   De Klerk, John M H ^b   Lips, Cornelis J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; RADIOACTIVE IODINE; THYROXINE;

DOSE RESPONSE; DRUG HALF LIFE; DRUG METABOLISM; EUTHYROIDISM; EVIDENCE BASED PRACTICE; HUMAN; HYPERTHYROIDISM; LETTER; RADIATION DOSE; SCINTIGRAPHY;

DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TREATMENT OUTCOME;

EID: 35349029285     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0592-1     Document Type: Letter

References (12)

1. Sisson JC, Avram AM, Rubello D, Gross MD. Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science? Eur J Nucl Med Mol Imaging 2007;34:1129-30.
2. Anonymous. Richtlijn Schildklierfunctiestoornissen [in Dutch] http://www.internisten.nl/files/ richtlijnschildklierfunctiestoornissendefinitiefmei2007.pdf
3. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M. Differences and similarities in the diagnosis and treatment of Graves'disease in Europe, Japan, and the United States. Thyroid 1991;1:129-35.
4. Allahabadia A, Daykin J, Sheppard MC, Gouch SCL, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001;86:3611-7.
5. Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Eur J Nucl Med 2001;28:1489-95.
6. DeGroot LJ, Stanbury JB. Graves' disease: diagnosis and treatment. In: DeGroot LJ, Stanbury JB, editors. The thyroid and its diseases, 4th edn. New York: Wiley; 1975. p. 314-67.
7. Aktay R, Rezai K, Seabold JE, Bar RS, Kirchner PT. Four- to twenty-four-hour uptake ratio: an index of rapid iodine-131 turnover in hyperthyroidism. J Nucl Med 1996;37:1815-9.
8. Himanka E, Larsson L. Estimation of thyroid volume. Acta Radiol 1955;43:125-31.
9. van Isselt JW, Beekman FJ, Kamphuis C, de Klerk JMH, Polman LJ, van Gils APG, Vincken K, van Rijk PP. Comparison of methods for thyroid volume estimation in patients with Graves' disease. Eur J Nucl Med Mol Imaging 2003;30:525-31.
10. van Isselt JW, de Klerk JMH, Koppeschaar HPF, van Rijk PP. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease. Nucl Med Commun 2000;21:609-16.
11. Berg GEB, Michanek AMK, Holmberg ECV, Fink M. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J Nucl Med 1996;37:228-32.
12. Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism. Cancer Biother Radiopharm 2005;20:218-23.